Indeed, the LSD1 inhibitor ORY-1001 is under clinical investigation in ALL and AML, in which inhibition of LSD1 was pro-differentiative, however not sufficient to induce cell death as monotherapy [275]. The gene discussed is KDM1A; the disease is acute lymphoblastic leukemia.